DrugInformer Search

Muscle Spasticity : Baclofen Vs. Botulinum Toxin Type A


Spasticity is a feature of altered skeletal muscle performance, occurring in disorders of the central nervous system (CNS) which give rise to the Upper Motor Neuron Syndrome. Muscles affected by the Upper Motor Neuron Syndrome have many other potential features of altered performance including weakness, decreased motor control, clonus (a series of involuntary rapid muscle contractions), exaggerated deep tendon reflexes and decreased endurance. The Upper Motor Neuron Syndrome occurs following damage to the central nervous system, when there is a loss of descending inhibition from the brain to the spinal cord, such that muscles become overactive. This loss of inhibitory control can cause an ongoing level of contraction, with decreased ability for the affected individual to volitionally control the muscle contraction, and increased resistance felt on passive stretch. A defining feature of spasticity is that the increased resistance to passive stretch is velocity-dependent, as described in the commonly cited definition of spasticity from Lance (1980): “a motor disorder, characterised by a velocity-dependent increase in tonic stretch reflexes (muscle tone) with exaggerated tendon jerks, resulting from hyper-excitability of the stretch reflex as one component of the upper motor neurone (UMN) syndrome”.

Read more on Wikipedia

Compare Drugs

Please add a drug to the list to compare them side by side.
Add a new Drug

* Warning: The facts and figures contained in these reports are accurate to the best of our capability; however, our metrics are only meant to augment your medical knowledge, and should never be used as the sole basis for selecting a new medication. As with any medical decision, be sure to work with your doctor to ensure the best choices are made for your condition.

* About FAERS: The FDA Adverse Event Reporting System (FAERS) is used by FDA for activities such as looking for new safety concerns that might be related to a marketed product, evaluating a manufacturer's compliance to reporting regulations and responding to outside requests for information. Reporting of adverse events is a voluntary process, and not every report is sent to FDA and entered into FAERS. The FAERS database may contain duplicate reports, the report quality is variable, and many factors may influence reporting (e.g., media attention, length of time a drug is marketed, market share). For these reasons, FAERS case reports cannot be used to calculate incidence or estimates of risk for a particular product or compare risks between products.